191 related articles for article (PubMed ID: 20096120)
1. Cancer cell sensitivity to bortezomib is associated with survivin expression and p53 status but not cancer cell types.
Ling X; Calinski D; Chanan-Khan AA; Zhou M; Li F
J Exp Clin Cancer Res; 2010 Jan; 29(1):8. PubMed ID: 20096120
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of proteasome activity by bortezomib in renal cancer cells is p53 dependent and VHL independent.
Vaziri SA; Grabowski DR; Hill J; Rybicki LR; Burk R; Bukowski RM; Ganapathi MK; Ganapathi R
Anticancer Res; 2009 Aug; 29(8):2961-9. PubMed ID: 19661301
[TBL] [Abstract][Full Text] [Related]
3. Small interfering RNA targeting survivin sensitizes lung cancer cell with mutant p53 to adriamycin.
Yonesaka K; Tamura K; Kurata T; Satoh T; Ikeda M; Fukuoka M; Nakagawa K
Int J Cancer; 2006 Feb; 118(4):812-20. PubMed ID: 16108013
[TBL] [Abstract][Full Text] [Related]
4. Can survivin expression predict the response to bortezomib in cases with mantle cell lymphoma?
Paydas S
Leuk Lymphoma; 2006 Nov; 47(11):2412-3. PubMed ID: 17107919
[No Abstract] [Full Text] [Related]
5. The p53-independent induction of apoptosis in breast cancer cells in response to proteasome inhibitor bortezomib.
Yerlikaya A; Okur E; Ulukaya E
Tumour Biol; 2012 Oct; 33(5):1385-92. PubMed ID: 22477712
[TBL] [Abstract][Full Text] [Related]
6. Loss of p53, rather than beta-catenin overexpression, induces survivin-mediated resistance to apoptosis in an esophageal cancer cell line.
Chang E; Donahue J; Smith A; Hornick J; Rao JN; Wang JY; Battafarano RJ
J Thorac Cardiovasc Surg; 2010 Jul; 140(1):225-32. PubMed ID: 20236666
[TBL] [Abstract][Full Text] [Related]
7. Synergistic interaction between the novel histone deacetylase inhibitor ST2782 and the proteasome inhibitor bortezomib in platinum-sensitive and resistant ovarian carcinoma cells.
Gatti L; Benedetti V; De Cesare M; Corna E; Cincinelli R; Zaffaroni N; Zunino F; Perego P
J Inorg Biochem; 2012 Aug; 113():94-101. PubMed ID: 22717676
[TBL] [Abstract][Full Text] [Related]
8. Proteasome inhibition with bortezomib enhances activity of topoisomerase I-targeting drugs by NF-kappaB-independent mechanisms.
Takigawa N; Vaziri SA; Grabowski DR; Chikamori K; Rybicki LR; Bukowski RM; Ganapathi MK; Ganapathi R; Mekhail T
Anticancer Res; 2006; 26(3A):1869-76. PubMed ID: 16827119
[TBL] [Abstract][Full Text] [Related]
9. Sensitization of DNA damage-induced apoptosis by the proteasome inhibitor PS-341 is p53 dependent and involves target proteins 14-3-3sigma and survivin.
Vaziri SA; Hill J; Chikamori K; Grabowski DR; Takigawa N; Chawla-Sarkar M; Rybicki LR; Gudkov AV; Mekhail T; Bukowski RM; Ganapathi MK; Ganapathi R
Mol Cancer Ther; 2005 Dec; 4(12):1880-90. PubMed ID: 16373703
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells.
Hideshima T; Catley L; Raje N; Chauhan D; Podar K; Mitsiades C; Tai YT; Vallet S; Kiziltepe T; Ocio E; Ikeda H; Okawa Y; Hideshima H; Munshi NC; Yasui H; Richardson PG; Anderson KC
Br J Haematol; 2007 Sep; 138(6):783-91. PubMed ID: 17760810
[TBL] [Abstract][Full Text] [Related]
11. Knockdown of survivin and upregulation of p53 gene expression by small interfering RNA induces apoptosis in human gastric carcinoma cell line SGC-823.
Lu YH; Wang K; He R; Xi T
Cancer Biother Radiopharm; 2008 Dec; 23(6):727-34. PubMed ID: 19111044
[TBL] [Abstract][Full Text] [Related]
12. Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma.
Gordon GJ; Mani M; Maulik G; Mukhopadhyay L; Yeap BY; Kindler HL; Salgia R; Sugarbaker DJ; Bueno R
Cancer Chemother Pharmacol; 2008 Apr; 61(4):549-58. PubMed ID: 17522864
[TBL] [Abstract][Full Text] [Related]
13. The proteasome inhibitor Bortezomib (Velcade) as potential inhibitor of estrogen receptor-positive breast cancer.
Thaler S; Thiede G; Hengstler JG; Schad A; Schmidt M; Sleeman JP
Int J Cancer; 2015 Aug; 137(3):686-97. PubMed ID: 25530422
[TBL] [Abstract][Full Text] [Related]
14. The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells.
Liu X; Yue P; Chen S; Hu L; Lonial S; Khuri FR; Sun SY
Cancer Res; 2007 May; 67(10):4981-8. PubMed ID: 17510429
[TBL] [Abstract][Full Text] [Related]
15. Rad knockdown induces mitochondrial apoptosis in bortezomib resistant leukemia and lymphoma cells.
Yeom SY; Lee SJ; Kim WS; Park C
Leuk Res; 2012 Sep; 36(9):1172-8. PubMed ID: 22658652
[TBL] [Abstract][Full Text] [Related]
16. The proteasome inhibitor bortezomib acts differently in combination with p53 gene transfer or cytotoxic chemotherapy on NSCLC cells.
Neukirchen J; Meier A; Rohrbeck A; Garcia-Pardillos G; Steidl U; Fenk R; Haas R; Kronenwett R; Rohr UP
Cancer Gene Ther; 2007 Apr; 14(4):431-9. PubMed ID: 17235352
[TBL] [Abstract][Full Text] [Related]
17. [Study on apoptosis of oral squamous carcinoma cell line KB and KBv200 induced by survivin RNAi].
Yan L; Chen WQ; Liang YJ; Dai CL; Wang XH; Shi Z; Chen LM; Fu LW
Ai Zheng; 2006 Aug; 25(8):933-40. PubMed ID: 16965671
[TBL] [Abstract][Full Text] [Related]
18. [Effect of silencing survivin gene on sensitivity of myeloma cells to adriamycin].
Li J; Zhao Y; Luo SK; Zhang DB; Huang BH
Ai Zheng; 2006 Dec; 25(12):1488-92. PubMed ID: 17166372
[TBL] [Abstract][Full Text] [Related]
19. Oxaliplatin-mediated inhibition of survivin increases sensitivity of head and neck squamous cell carcinoma cell lines to paclitaxel.
Khan Z; Khan N; Varma AK; Tiwari RP; Mouhamad S; Prasad GB; Bisen P
Curr Cancer Drug Targets; 2010 Nov; 10(7):660-9. PubMed ID: 20578991
[TBL] [Abstract][Full Text] [Related]
20. Downregulation of survivin by RNAi inhibits growth of human gastric carcinoma cells.
Miao GY; Lu QM; Zhang XL
World J Gastroenterol; 2007 Feb; 13(8):1170-4. PubMed ID: 17451195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
